How profitable is YD Bio Limited (YDES)?

In FY 2025 (10-K), YDES converted $1.0M of revenue into a 16.7% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Stock Ratings / Health Care / YDES / financials

FLGT (31) BDSX (40) TLSI (30) XGN (36) ⌘ Pro Terminal →

YD Bio Limited (YDES) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$5.97 +0.51% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.96

YD Bio Limited (YDES) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $420.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on YDES Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is YDES stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, YD Bio Limited (NASDAQ: YDES) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $5.97 (+0.51% 1D, market cap $420.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does YDES compare to FLGT and BDSX in the Health Care sector?

▼

Within the Health Care sector (Medical Specialities), YDES carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 28.1%, and ROIC of -20.0%. By comparison, FLGT (Fulgent Genetics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -6.8%, cap $567.4M) and BDSX (Biodesix Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $245.4M). Among the 5-stock peer group, YDES leads on earnings multiple (N/A) while FLGT leads on capital efficiency (-6.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for YDES?

▼

Per YDES's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002011674), YD Bio Limited generated $596.8K in revenue (+16.9% YoY), -$8.3M in net income, and -$8.0M in free cash flow against $13.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.96 (-0.10%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-6.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for YDES)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (44/100 Composite)

🔍 WHY YDES SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (32% of score)

Altman Z-Score 13.44 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (23% of score)

FRED Regime × Technicals: 30% of 52W Range • RSI-14 at 52.3 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$6.10-4.3% Next Q

Q2 (-2Q)

Grade D$5.84+3.4% Next Q

Q3 (-1Q)

Grade D$6.04-1.2% Next Q

Current

Grade D$5.97-6.5% Hist 90D α

Trajectory: C- (52) → D (44)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a YDES Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While YDES currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.17) and Max Pain ($6.27) forces dealer call-delta covering toward $16.51.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $YDES• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “YDES Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 44%NO 56%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How YDES Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $350.1K

FY24

Rev $510.4K

FY25

Rev $596.8K

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$596.8K	28.1%	-80%	-$8.3M	-$8.0M	-45%
FY 2024	$510.4K	30.4%	-80%	-$1.4M	-$1.3M	-33.4%
FY 2023	$350.1K	28.1%	-2.8%	$13.6K	-$55.7K	-20%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring YDES)

✓Walkthrough of YDES's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

YDES // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +18.92%▲ ASCENDING CHANNEL

2026-11-03O $5.87H $5.97L $5.87C $5.97VOL 47.4K

RES: $9.08SUP: $2.79SMA50: $5.17SMA200: $5.47

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

YDES Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 YDES Butterfly Map → + Track YDES →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +16.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on YDES today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for YDES. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for YDES today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (YDES)

Health Care Rank #393 of 1016 ⚔️ FLGT vs YDES Full Matrix →

1. Head-to-Head Health Care Peer Comparison (YDES vs. FLGT, BDSX, TLSI, XGN)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, YD Bio Limited (YDES) ranks #393 by composite RQD confidence (44/100, grade D) and #467 by equity capitalization ($420.7M). Within this direct 5-issuer industry benchmark cohort, YDES leads on earnings valuation at N/A trailing P/E, while FLGT leads on capital efficiency and profitability with -6.8% ROIC and 40.6% gross margin. YDES currently leads its immediate peer cohort in composite quantitative strength at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
YDES ACTIVE YD Bio Limited	D	44/100	—	28.1%	-20.0%	+0.51%	$420.7M	Benchmark Subject
FLGT Fulgent Genetics Inc.	E	31/100	—	40.6%	-6.8%	-6.45%	$567.4M	/flgt-vs-ydes →
BDSX Biodesix Inc.	D-	40/100	—	—	-35.0%	-6.34%	$245.4M	/bdsx-vs-ydes →
TLSI TriSalus Life Sciences Inc.	E	30/100	—	84.6%	-35.0%	-1.89%	$227.8M	/tlsi-vs-ydes →
XGN Exagen Inc.	D-	36/100	—	58.3%	-35.0%	-2.33%	$208.1M	/xgn-vs-ydes →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002011674

In its most recent audited fiscal period (FY2025, filed 2025-12-31), YD Bio Limited (YDES) reported GAAP revenue of $596.8K (+16.9% vs. FY2024 revenue of $510.4K , and +70.5% cumulative change since FY2023) , GAAP net income of -$8.3M, operating cash flow of -$6.6M, and free cash flow of -$8.0M (-519.4% YoY). On the balance sheet, YDES closed FY2025 with $13.8M in total assets against $0 in total debt (Altman Z-Score: 13.44, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$596.8K	-$8.3M	-$6.6M	-$8.0M	$13.8M	—
FY2024 (FY)	2024-12-31	$510.4K	-$1.4M	-$1.2M	-$1.3M	$6.9M	—
FY2023 (FY)	2023-12-31	$350.1K	$13.6K	-$55.7K	-$55.7K	—	—

3. YDES Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is YDES stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does YDES compare to FLGT and BDSX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for YDES?

Where is YDES trading relative to its 50-day, 200-day, and 52-week technical levels?

YDES last traded at $5.97 (+0.51% on volume of 180,252 shares), positioning the stock +15.47% above its 50-day simple moving average ($5.17) and +9.14% above its 200-day simple moving average ($5.47). Across its 52-week range of $1.70 to $15.72, YDES sits at the 30.5% percentile with a 14-day RSI of 52.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.22 to $6.72).

Direct Sub-Reports: YDES RQD Cockpit YDES 12M Forecast YDES Earnings & Move YDES Dividends & DRIP YDES Insiders & 13F YDES Whale Options YDES Profit Sankey YDES News & Why

ROARABLE RATING BRIEF • RQD 44/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

YDES — YD Bio Limited: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:36:49Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

YDES scores 44 out of 100, a letter grade of D, with the verdict label "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 8 / 20 (ROIC -20%; FCF yield -1.93%); Whale 13F Flow at 9 / 20 (institutional accumulation and options positioning); Insider Conviction at 3 / 20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 10 / 20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 14 / 20 (Altman Z 13.44; Piotroski F 4/9; Debt/Equity 0.5). The weakest pillar is insider conviction, and the cash engine is also weak given negative ROIC and negative free-cash-flow yield. The forensic balance sheet is the strongest pillar, with a high Altman Z-Score and a low Debt/Equity ratio, though the Piotroski F-Score of 4/9 is mid-range rather than strong. For a prospective investor, the practical implication is that the rating weighs current cash generation and insider signals heavily against the stock; the balance-sheet strength provides some cushion, but the cash-flow and insider pillars are the primary reasons for the underperform label.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Per the recent news wire, the company has been associated with a no-blood-draw questionnaire for cancer risk assessment and a $10 AI cancer risk assessment tool. — describes its specific customer base or revenue model beyond these headlines. Reported revenue is small, at $0.6M for FY 2025, and the company operates at a negative operating margin of -60%.

Losses widened from FY 2023 to FY 2025 while revenue grew modestly, from $0.4M to $0.6M. The gross margin is 28.1% per the market data, but operating and net margins are both -60%, and ROIC is -20%. The Altman Z-Score is 13.44 and the Piotroski F-Score is 4/9, with a Debt/Equity ratio of 0.5. Cash rose to $6.0M in FY 2025 from $3.1M in FY 2024, but free cash flow was -$8.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: The Forensic Balance Sheet pillar scores 14 / 20 with Altman Z 13.44 and Debt/Equity 0.5, and cash rose to $6.0M in FY 2025. With Fundamental Cash Engine at 8/20 (ROIC -20.0%, FCF yield -1.93%) and Institutional Whale Flow at 9/20, sustained execution supports upside toward the top of the $1.70 – $15.72 52-week range.
🐻 Primary Bear Case: ROIC is -20%, FCF yield is -1.93%, and FY 2025 net loss of -$8.3M widened against $0.6M revenue, with insider conviction at 3 / 20. Investors must weigh current valuation against -60.0% operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Supply chain is NONE and butterfly links are empty. Upstream and downstream dependencies are — Sector correlation data is not provided beyond the Beta of 1.0 in the market data and the Roarable RQD rating's reference to sector sensitivity. The second-order items a prospective investor should watch are the cash burn trajectory (FCF of -$8.0M in FY 2025 against $6.0M cash) and whether the risk-watch cancer-screening product headlines translate into reported revenue, since reported revenue is currently under $1M.

Key Question #1: What are the trailing EPS and P/E figures, given that EPS is N/A across all reported periods?
Key Question #2: What is the debt position, given that debt is N/A in every reported period while Debt/Equity is listed as 0.5?
Key Question #3: What drove the rise in cash from $3.1M to $6.0M in FY 2025 while free cash flow was negative?

YDES Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for YD Bio Limited (YDES) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to YDES Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 20h ago

YD Bio Limited Estimates – NASDAQ:YDES

TradingView report covering YD Bio Limited (YDES) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Stock Titan • 23h ago

A no-blood-draw questionnaire brings cancer risk assessment to a workplace wellness app

Stock Titan report covering YD Bio Limited (YDES) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Investing.com India • 1d ago

YD Bio launches $10 AI cancer risk assessment tool By Investing.com

Investing.com India report covering YD Bio Limited (YDES) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.siam.in/ • 1d ago

YD (YDES) Gains +1.39% — Support Holds at $5.56 2026-10-22 - Backspread Trade

https://www.siam.in/ report covering YD Bio Limited (YDES) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Aspen Neuroscience (ASPE) Stock Price, News & Analysis

Stock Titan report covering YD Bio Limited (YDES) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 11d ago

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers Profusa (NASDAQ:PFSA) shares moved upwards by 35.4% to $1.15 during Thursday's regular session. Karyopharm Therapeutics (NASDAQ:KPTI) shares increased by 29.12% to $0.55. The company's market cap

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 13d ago

YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs

TAIPEI, Taiwan, and BOTHELL, Wash., Oct. 20, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection and ophthalmologic

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

YDES Bull vs. Bear Conversation Board — What's Your Call at $5.97?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON YDES 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull Growth & Tech Investor 🐂 BULLISH 🎯 Target: $7.31 (+23.1%)

📌 Pinned Debate

The Forensic Balance Sheet pillar scores 14 / 20 with Altman Z 13.44 and Debt/Equity 0.5, and cash rose to $6.0M in FY 2025.

The street is overcomplicating YD Bio Limited (YDES). The Forensic Balance Sheet pillar scores 14 / 20 with Altman Z 13.44 and Debt/Equity 0.5, and cash rose to $6.0M in FY 2025.. With an RQD score of 44/100 (D) and Forensic Balance Sheet at 14/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $6.42.

ArenaChamp_24 🐂 BULL

@ForensicBear Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical Specialities. If gross margin (28.1%) holds, EPS grows into the multiple faster than bears think.

FO ForensicBear 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $5.11 (-14.0%)

Spot @ $5.94

ROIC is -20%, FCF yield is -1.93%, and FY 2025 net loss of -$8.3M widened against $0.6M revenue, with insider conviction at 3 / 20.

Careful chasing YDES at $5.94. ROIC is -20%, FCF yield is -1.93%, and FY 2025 net loss of -$8.3M widened against $0.6M revenue, with insider conviction at 3 / 20.. Gross margin is 28.1%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $5.11 on multiple compression.